Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 3NETWORK 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 479Lymphoid 283Other hematologic neoplasm 191Gastrointestinal 36Breast 25Genitourinary 24Thoracic 19CNS 19Myeloid 16Head & Neck 14Tumor-Agnostic 13Gynecologic 10Dermatologic 8Sarcoma 6Other solid neoplasm 5Other 5Other neoplasm 1Endocrine 1Classical hematology 1

Conditions

beta-Thalassemia 1Thalassemia 1Anemia, Sickle Cell 1

Interventions

Cyclophosphamide 79fludarabine phosphate 75Busulfan 53Whole-Body Irradiation 51Mycophenolic Acid 50Cyclosporine 47Peripheral Blood Stem Cell Transplantation 46fludarabine 42Antilymphocyte Serum 37Melphalan 36Tacrolimus 35Filgrastim 30Cord Blood Stem Cell Transplantation 27Radiotherapy 23Methotrexate 22Cytarabine 22Methylprednisolone 19Granulocyte Colony-Stimulating Factor 18apixaban 17Thiotepa 17Dalteparin 13thymoglobulin 12Rivaroxaban 12Alemtuzumab 12eltrombopag 11ferric carboxymaltose 10Surveys and Questionnaires 10Etoposide 10Epoetin Alfa 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Dexamethasone × Classical hematology × Clear all
NCT05736419 2026-04-08

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡